[ad_1]
The Saudi Ministry of Health has revealed that Vitrakvi is the trade name of Larotrectinib and that the drug does not completely treat cancer, as mentioned earlier.
The new drug aims to control its growth and spread for as long as possible and is not a substitute for surgical treatment, chemotherapy and radiation therapy.
She also noted that the new treatment was recently adopted by the US Food and Drug Administration to treat specific cancer cases with a specific type of rare genetic mutations "TRK gene".
This rare mutation is present in certain tumors, such as the salivary gland, the thyroid, the lung and the connective tissue, as well as in the treatment of cases containing a genetic mutation and unable to tolerate surgery, as well as cases containing a genetic mutation and not having an appropriate alternative to treatment and cases arising after treatment.
The New England Journal of Medicine has published a study on treatment with larotrectinib, which was in its first and second stages. It involved 55 patients with cancer who had the TRK gene mutation. The complete response rate was 13% and the partial response rate was 62%. This response did not last long in all patients, as the disease developed in some study participants and continued to respond in 39% of patients after the first year of treatment, and some patients were operated on after treatment.
[ad_2]
Source link
